Adverse Reactions, Labelling and Mayo Clinic

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Adverse Reactions

Labelling

Mayo Clinic

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

JULY 9, 2025

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). Mayo Clinic. million individuals in the United States aged 65 and older.

Labelling

Labelling Pharmacy Technician Independent Pharmacies Compounding Pharmacies

Over-the-Counter Choices Pharmacist Role and Resources

FADIC

JULY 14, 2024

OTC drugs come in various forms, including tablets, capsules, creams, and liquids, and are generally labeled with clear instructions on proper usage and dosage. The FDA’s website provides a wealth of information on OTC drugs, including product labels, warnings, and recalls.

Adverse Reactions

Adverse Reactions Dosage Mayo Clinic Medical Schools

Pharmacist Digest

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Over-the-Counter Choices Pharmacist Role and Resources

Stay Connected